Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease
- PMID: 11673605
- DOI: 10.1212/wnl.57.8.1515
Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease
Abstract
The antioxidant N-acetylcysteine (NAC) or placebo was administered in a double-blind fashion to patients who met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for probable AD. Testing for efficacy occurred after 3 and 6 months of treatment. Comparison of interval change favored NAC treatment on nearly every outcome measure, although significant differences were obtained only for a subset of cognitive tasks.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous